During the first 6 months after its establishment, the MKSC assessed 42 new AIDS-KS patients.
 It is notable that although just over half of the patients had undetectable VLs at time of assessment by the MKSC, more than two-thirds still had suboptimal KS responses on ART alone.
 When the MKSC was started, all patients with AIDS-KS were seen regardless of T stage, but referral criteria have since been limited to T1 patients.
 The MKSC is regularly confronted with difficult treatment decisions that are complicated by late referrals, poor PS, serious co-infections and poor adherence to treatment.
[5,6] This is in keeping with international guidelines and the current protocol of the MKSC in which chemotherapy with combination bleomycin and vincristine or paclitaxel as single agent is used in all patients considered fit for chemotherapy.
 On a practical level, this addresses the often difficult decision the MKSC had to make when faced with very unwell patients.